Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity

Yun Wang,* Daniela Botolin,* Jinghua Xu,† Barbara Christian,*, Ernestine Mitchell,*, Boldeedula Jayaprakasam,§ Muraleedharan Nair,§ Jeffery M. Peters,** Julia Busik,*, L. Karl Olson,* and Donald B. Jump*†,†

Departments of Physiology,* Biochemistry and Molecular Biology,† and Horticulture,§ Michigan State University, East Lansing, MI 48824; and Department of Veterinary Science and Biomedical Sciences,** Center for Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, PA 16802

Abstract Fatty acid elongases and desaturases play an important role in hepatic and whole body lipid composition. We examined the role that key transcription factors played in the control of hepatic elongase and desaturase expression. Studies with peroxisome proliferator-activated receptor α (PPARα)-deficient mice establish that PPARα was required for WY14643-mediated induction of fatty acid elongase-5 (Elovl-5), Elovl-6, and all three desaturases (Δ5 desaturase (Δ5D), Δ6D, and Δ5D). Increased nuclear sterol-regulatory element binding protein-1 (SREBP-1) correlated with enhanced expression of Elovl-6, Δ5D, Δ6D, and Δ5D. Only Δ5D was also regulated independently by liver X receptor (LXR) agonist. Glucose induction of t-type pyruvate kinase, Δ5D, and Elovl-6 expression required the carbohydrate-regulatory element binding protein/MAX-like factor X (ChREBP/MLX) heterodimer. Suppression of Elovl-6 and Δ5D expression in livers of streptozotocin-induced diabetic rats and high fat-fed glucose-intolerant mice correlated with low levels of nuclear SREBP-1. In leptin-deficient obese mice (Lept<sub>ob/ob</sub>), increased SREBP-1 and MLX nuclear content correlated with the induction of Elovl-5, Elovl-6, and Δ5D expression and the massive accumulation of monounsaturated fatty acids (18:1n-7 and 18:1n-9) in neutral lipids. Diabetes- and obesity-induced changes in hepatic lipid composition correlated with changes in elongase and desaturase expression. In conclusion, these studies establish a role for PPARα, LXR, SREBP-1, ChREBP, and MLX in the control of hepatic fatty acid elongase and desaturase expression and lipid composition.—Wang, Y., D. Botolin, J. Xu, B. Christian, E. Mitchell, B. Jayaprakasam, M. Nair, J. M. Peters, J. Busik, L. K. Olson, and D. B. Jump. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J. Lipid Res. 2006. 47: 2028–2041.

Supplementary key words peroxisome proliferator-activated receptor α • sterol-regulatory element binding protein-1 • carbohydrate-regulatory element binding protein • MAX-like factor X • liver X receptor

The liver plays a central role in whole body lipid metabolism. Fatty acids are synthesized de novo from glucose. This pathway uses products from glycolysis and, along with the two enzymes acetyl-coenzyme A carboxylase (ACC) and fatty acid synthase, generates palmitate (16:0). Insulin, triiodothyronine (T<sub>3</sub>), glucocorticoids, and glucose induce, and C<sub>20</sub> PUFAs, glucagon, and epinephrine suppress, de novo lipogenesis (1–3). The liver also modifies fatty acid structure through metabolic pathways that include desaturation, elongation, mono-oxidation, and peroxisomal β-oxidation (chain shortening). Such modifications occur to fatty acids generated de novo as well as fatty acids derived from the diet. These pathways are particularly critical for the generation of end products of PUFA synthesis. Arachidonic acid (20:4n-6) and docosahexaenoic acid (22:6n-3) are the main C<sub>20-22</sub> PUFAs accumulating in membranes of all tissues (4). Together, these metabolic pathways play an important role in the maintenance of membrane lipid composition and lipid storage, the generation of precursors for signaling molecules, such as eicosanoids, and the control of fatty acid-regulated transcription factors (2, 5, 6).

Of the various pathways known to affect fatty acid structure, physiological control of fatty acid elongation remains poorly defined. The predominant pathway for fatty acid elongation occurs in the endoplasmic reticulum and uses malonyl-CoA and fatty acyl-CoA as substrates for the addition of two carbons to fatty acids. Elongases are condensing enzymes that interact with 3-keto acyl-CoA reductase, a

Abbreviations: ACC, acetyl-coenzyme A carboxylase; ChoRE, carbohydrate-regulatory element; ChREBP, carbohydrate-regulatory element binding protein; Δ5,Δ6 desaturase; Elovl-1, fatty acid elongase-1; HNF-4, hepatic nuclear factor-4; L-PK, t-type pyruvate kinase; Luc, luciferase; LXR, liver X receptor; MLX, MAX-like factor X; PPARα, peroxisome proliferator-activated receptor α; qRT, quantitative realtime; SREBP-1, sterol-regulatory element binding protein-1; T1317, T0901317; T<sub>3</sub>, triiodothyronine.

Yun Wang, Daniela Botolin, and Jinghua Xu contributed equally to this work.

2 To whom correspondence should be addressed.

e-mail: jump@msu.edu

Copyright © 2006 by the American Society for Biochemistry and Molecular Biology, Inc.

This article is available online at http://www.jlr.org
dehydratase, and trans-2,3-enoyl-CoA reductase to elongate fatty acids (7–9). The rate of fatty acid elongation is determined by the activity of the elongase (condensing enzyme) and not the reductases or the dehydratase. Seven distinct fatty acid elongase subtypes [fatty acid elongase-1 (Elov-1) through Elov-7] are present in the mouse, rat, and human genomes (www.ensembl.org). Elov-1 (Ssc1) and Elov-6 (LCE, FACE, rElo2) elongate saturated and monounsaturated fatty acids. Elov-6 is induced in transgenic mice overexpressing sterol-regulatory element binding protein-1 (SREBP-1) (10–12). Elov-2 (Ssc2) substrates include C_{20–22} PUFAs, whereas Elov-5 (FAE1, R elo1, Helo1) uses a broad substrate array, C_{16–22} (10, 13). Elov-2 and Elov-5 likely play a role in endogenous PUFA synthesis [i.e., the conversion of the essential fatty acid precursors linoleic acid (18:2,n-6) and arachidonic acid (20:4,n-6) to docosahexaenoic acid (22:6,n-3)]. Elov-3 (Cig30, Elo3) and Elov-4 (Elo4) are expressed in the skin (14) and retina (15), respectively. Both Elovl-3 and Elovl-4 elongate a broad array of fatty acids (11). Elovl-7 has not been characterized.

Animals

All procedures for the use and care of animals for laboratory research were approved by the All University Committee for Animal Use and Care at Michigan State University.

Streptozotocin-induced diabetes. Male Sprague-Dawley rats (200–250 g; Charles River Laboratories, Kalamazoo, MI) were maintained on Harlan-Teklad laboratory chow (No. 8640) and water ad libitum. Rats were injected intraperitoneally with streptozotocin (7.5 mg/100 g body weight) and 3 ml of 25% glucose (18). Three weeks later, blood glucose was measured in animals receiving no streptozotocin (control) or streptozotocin (diabetic; blood glucose ≥ 120 mg/dl). Blood glucose was measured in isoflurane-anesthetized rats using a glucose meter (Freestyle Flash; Thera Sense, Inc., Alameda, CA). Control and diabetic rats were euthanized (isoflurane anesthesia and exsanguination) for recovery of blood (plasma) and liver.

High-fat feeding of C57BL/6 mice. Male C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME), 2 months of age, were fed diets containing 10% lard (D12450B) or 60% lard (D12492; Research Diets, Inc.) ad libitum for 10 weeks. Four days before euthanasia, mice were subjected to a glucose tolerance test. Briefly, mice were injected with glucose (2 g/kg ip). Blood was withdrawn from the tail vein before and after glucose treatment. Blood glucose was measured using a handheld glucose meter (Freestyle Flash; Thera Sense, Inc.). Mice were euthanized using isoflurane and exsanguinated; blood and liver were recovered. Livers were used for RNA and lipid extraction.

Lean and obese mice. Livers from lean and obese C57BL/6 mice were obtained from Drs. D. Romsos and K. Claycomb (Department of Food Science and Human Nutrition, Michigan State University). Lean (C57BL/6J-Lep^{+/+}) and obese (C57BL/6J-Lep^{−/−}) mice (B6.V-Lep ob/J, No. 000632; Jackson Laboratories) were maintained on a Harlan-Teklad laboratory chow (No. 8640) diet and water ad libitum. Livers were used for RNA, lipid, and protein extraction.

Wild-type and PPARα-deficient mice. Homozygous wild-type and PPARα-deficient (PPARα^{−/−}) mice on a Sv/129 genetic background (19, 20) were fed either a control diet or one containing Wy14643 (at 50 or 500 mg/kg; Bio-Serv, Piscataway, NJ) for 1 week. Mice were euthanized, livers were removed, and RNA was isolated for analysis of gene expression.

Primary rat hepatocytes. Male Sprague-Dawley rats (Charles River Laboratories) were maintained on Harlan-Teklad laboratory chow (No. 8640) and water ad libitum. Rat primary hepatocytes were prepared from Teklad chow-fed (ad libitum) male Sprague-Dawley rats and cultured on BioCoat (type 1 collagen) plates (Beckon Dickinson, Bedford, MA) (21). For RNA and protein extraction, cells were plated onto 100 mm type I collagen-coated plates (BD Bioscience, Bedford, MA) at 10^5 cells/plate in Williams E (Gibco/In vitrogen, Carlsbad CA), 10 mM lactate, 10 nM dexamethasone, 1 μM insulin (Sigma, St. Louis, MO), and 10% fetal bovine serum (Gibco/Invitrogen). For adenoviral infection studies, cells were plated in the same medium onto six-well type 1 collagen-coated plates at 1.5 × 10^6 cells/well. The ratio of culture medium to cell number was maintained constant for the different plating conditions. For treatments, hepatocytes were incubated in medium [Williams E + 10 nM dexamethasone with or without 1 μM (0.17 U/ml) insulin and/or 25 mM glucose].

**Materials and Methods**

**Human liver tissue**

Human liver was obtained from the National Disease Research Interchange (Philadelphia, PA).

**Animals**

All procedures for the use and care of animals for laboratory research were approved by the All University Committee for Animal Use and Care at Michigan State University.

**Streptozotocin-induced diabetes.** Male Sprague-Dawley rats (200–250 g; Charles River Laboratories, Kalamazoo, MI) were maintained on Harlan-Teklad laboratory chow (No. 8640) and water ad libitum. Rats were injected intraperitoneally with streptozotocin (7.5 mg/100 g body weight) and 3 ml of 25% glucose (18). Three weeks later, blood glucose was measured in animals receiving no streptozotocin (control) or streptozotocin (diabetic; blood glucose ≥ 120 mg/dl). Blood glucose was measured in isoflurane-anesthetized rats using a glucose meter (Freestyle Flash; Thera Sense, Inc., Alameda, CA). Control and diabetic rats were euthanized (isoflurane anesthesia and exsanguination) for recovery of blood (plasma) and liver.

**Lean and obese mice.** Livers from lean and obese C57BL/6 mice were obtained from Drs. D. Romsos and K. Claycomb (Department of Food Science and Human Nutrition, Michigan State University). Lean (C57BL/6J-Lep^{+/+}) and obese (C57BL/6J-Lep^{−/−}) mice (B6.V-Lep ob/J, No. 000632; Jackson Laboratories) were maintained on a Harlan-Teklad laboratory chow (No. 8640) diet and water ad libitum. Livers were used for RNA, lipid, and protein extraction.

**Wild-type and PPARα-deficient mice.** Homozygous wild-type and PPARα-deficient (PPARα^{−/−}) mice on a Sv/129 genetic background (19, 20) were fed either a control diet or one containing Wy14643 (at 50 or 500 mg/kg; Bio-Serv, Piscataway, NJ) for 1 week. Mice were euthanized, livers were removed, and RNA was isolated for analysis of gene expression.

**Primary rat hepatocytes.** Male Sprague-Dawley rats (Charles River Laboratories) were maintained on Harlan-Teklad laboratory chow (No. 8640) and water ad libitum. Rat primary hepatocytes were prepared from Teklad chow-fed (ad libitum) male Sprague-Dawley rats and cultured on BioCoat (type 1 collagen) plates (Beckon Dickinson, Bedford, MA) (21). For RNA and protein extraction, cells were plated onto 100 mm type I collagen-coated plates (BD Bioscience, Bedford, MA) at 10^5 cells/plate in Williams E (Gibco/Invitrogen, Carlsbad CA), 10 mM lactate, 10 nM dexamethasone, 1 μM insulin (Sigma, St. Louis, MO), and 10% fetal bovine serum (Gibco/Invitrogen). For adenoviral infection studies, cells were plated in the same medium onto six-well type 1 collagen-coated plates at 1.5 × 10^6 cells/well. The ratio of culture medium to cell number was maintained constant for the different plating conditions. For treatments, hepatocytes were incubated in medium [Williams E + 10 nM dexamethasone with or without 1 μM (0.17 U/ml) insulin and/or 25 mM glucose].

**RNA extraction, Northern analysis, and quantitative real-time PCR**

Total RNA was extracted from primary hepatocytes or liver samples and used as a template for quantitative real-time (qRT) PCR or Northern analysis as described previously (17, 22). Specific primers for each gene (Table 1) were designed using Primer Express software (Applied Biosystems, Foster City, CA). First-strand cDNA was synthesized using SuperScript II RNase H reverse transcriptase (Invitrogen). Synthesized cDNA was mixed with 2X SYBR Green PCR Master Mix (Applied Biosystems) and various sets of gene-specific forward and reverse primers and subjected to real-time PCR quantification using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). All
TABLE 1. Primers for quantitative reverse transcriptase-polymerase chain reaction

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elovl-1</td>
<td>CCCTACCTTTTGGTGGAAGAA</td>
<td>TCCAGATGAGGTGGATGATG</td>
</tr>
<tr>
<td>Elovl-2</td>
<td>TTTGCGTGTCATCTTGCTC</td>
<td>GGGAGAAGCTTCCTTCGTC</td>
</tr>
<tr>
<td>Elovl-5</td>
<td>TACCACAGCTGCCACTATGCT</td>
<td>GAGGCTAGTAGAGACGTTGGA</td>
</tr>
<tr>
<td>Elovl-6</td>
<td>CAGCAGCATTGAAGACATGTTT</td>
<td>GTGAGGCTTACGCTTGGA</td>
</tr>
<tr>
<td>Δ(^D)D</td>
<td>TGGAGACAAAAGCTGTGGTGA</td>
<td>GTTGAGGCTAGCTGGTAGA</td>
</tr>
<tr>
<td>Δ(^D)D</td>
<td>TGTCACACAGTTTGTGCTGA</td>
<td>AGACGTCGGAGCTTCTTGTA</td>
</tr>
<tr>
<td>Δ(^D)D</td>
<td>ATCATTCACTCAGGGGAAAGA</td>
<td>CCATCTGCAGTGGGAAAGAC</td>
</tr>
<tr>
<td>LXRe</td>
<td>TCACGATCTCAGCAGGGA</td>
<td>TTATAGCACTGGGAGGAA</td>
</tr>
<tr>
<td>LXRe</td>
<td>AAAGCTGAGACGCTGCC</td>
<td>CGGCGACGCTTGCCTGGTA</td>
</tr>
<tr>
<td>SREBP-1c</td>
<td>GATTGCACATTTGAAGAC</td>
<td>GGATGGCAAGATGCGTGGTTG</td>
</tr>
<tr>
<td>β-Actin</td>
<td>ACTATTGGCAACGAGGCTT</td>
<td>TGTGACAAATGGCGGTTA</td>
</tr>
<tr>
<td>Mouse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elovl-1</td>
<td>CCCTACCTTTTGGTGGAAGAA</td>
<td>ATCCAGATGAGGTGGATGATG</td>
</tr>
<tr>
<td>Elovl-2</td>
<td>ACCTGTCCTCAGTTCCTT</td>
<td>GCCACATTAAATGCGTGGTTT</td>
</tr>
<tr>
<td>Elovl-5</td>
<td>GTTCGAGGGTCCAGGATTA</td>
<td>CCGCTCAGGGGATCTTCC</td>
</tr>
<tr>
<td>Δ(^D)D</td>
<td>TGGAGATTGAGACGCTTGGA</td>
<td>GTGAGGCTTACGCTTGGA</td>
</tr>
<tr>
<td>Δ(^D)D</td>
<td>CACGACGATTCCAGGAA</td>
<td>GGGGAGATTTACGCTGTCA</td>
</tr>
<tr>
<td>Δ(^D)D</td>
<td>TACAGTCAGGCTTGTGCTGA</td>
<td>CTCCTGCGTACGCTGTCC</td>
</tr>
<tr>
<td>Cyclophilin</td>
<td>CTTCTTGCTGTGCTCCTG</td>
<td>GGATGCGAAGATGCGTGGTTG</td>
</tr>
<tr>
<td>β-Actin</td>
<td>GAGCCGCGACCAGCTCATAT</td>
<td>CCGTGATCAAGCCGACT</td>
</tr>
<tr>
<td>Human</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elovl-1</td>
<td>GCTGGCGGACGAGCTATACTG</td>
<td>TCAGTCCTAGAACTGCGGGA</td>
</tr>
<tr>
<td>Elovl-2</td>
<td>CCCCTGCTGGCTTGCTACCTT</td>
<td>CAGGGCTTCGCTGATCTTC</td>
</tr>
<tr>
<td>Elovl-3</td>
<td>GTTCGACATCAGGCTGTTT</td>
<td>GTGACATCTCAGGGGCTT</td>
</tr>
<tr>
<td>Δ(^D)D</td>
<td>ATCCACGGCAGTGGGAA</td>
<td>GACAGCGTACGCTGTGA</td>
</tr>
<tr>
<td>Δ(^D)D</td>
<td>TTGCGACGACGATGCTACCTT</td>
<td>CGTGTCACCACGCACA</td>
</tr>
<tr>
<td>Cyclophilin</td>
<td>CTTCTTGCTGTGCTCCTG</td>
<td>GGATGCGAAGATGCGTGGTTG</td>
</tr>
<tr>
<td>β-Actin</td>
<td>GAGCCGCGACCAGCTCATAT</td>
<td>CCGTGATCAAGCCGACT</td>
</tr>
</tbody>
</table>

Δ\(^D\)D, Δ\(^D\) desaturase; Elovl-1, fatty acid elongase-1; LXRe, liver X receptor.

Lipid extraction and quantitation of hepatic fatty acid composition

Total lipid was extracted from liver in chloroform-methanol (2:1) plus 1 mM butyraldehyde. Total lipids were saponified, fractionated, and quantified by reverse-phase HPLC using a YMC J-Sphere (ODS-H80) column and a gradient starting at 77.5% acetonitrile to 100% acetonitrile (19:1) and ending at 100% acetonitrile (19:1) and ending at 100% acetonitrile (19:1). Lipids were analyzed by reverse-phase HPLC using a YMC J-Sphere (ODS-H80) column and a gradient starting at 77.5% acetonitrile to 100% acetonitrile (19:1) and ending at 100% acetonitrile (19:1).

Recombinant adenovirus

Cloning of cDNA for Elovl-2, Elovl-5, and Elovl-6 was described previously (17). The coding region for each transcript was ligated into the Ad-Easy XL adenoviral vector system (Stratagene), recombinant in BJ 5183 cells, and propagated in XL10 Gold ultracompetent cells. Adenovirus was packaged into Adenoviral particles in Ad-293 cells. The resulting adenovirus was amplified in HEK292 cells.

Immunoblotting

Liver microsomal and nuclear extracts were prepared as described previously (17, 23). Proteins (50–100 μg) extracted from microsomal or nuclear fractions were separated electrophoretically by SDS-PAGE (NuPAGE 4–12% polyacrylamide Bis-Tris; Invitrogen) and transferred to nitrocellulose membranes. Membranes were incubated with antibodies for SREBP-1 (IgG-2A4, sc-13551; Santa Cruz Biotechnology, Santa Cruz, CA) and SREBP-2 (IgG-7D4, monoclonal antibody). Hepatic nuclear factor-4 (HNF-4α; C-19), MLX (N-17), and anti-goat and anti-rabbit antibodies were obtained from Santa Cruz Biotechnology. ChREBP antibody was obtained from Novus Biologicals (Littleton, CO). Anti-mouse and anti-rabbit secondary antibodies were obtained from Bio-Rad; anti-goat antibodies were obtained from Santa Cruz Biotechnology. The SuperSignal West Pico chemiluminescence kit (Pierce) detection system was used.
In vitro fatty acid elongation assay

Rat liver microsomes were isolated by differential centrifugation (23). Elongation reactions were carried out with modifications to the procedure described by Moon et al. (10). Briefly, reaction mixtures contained 50 μg of microsomal proteins in a total reaction volume of 100 μl. The reaction constituents were as follows: 50 mM potassium phosphate buffer, pH 6.5, 5 μM rotenone (Sigma), 40 μM fatty acyl-CoA (Araniti Polar Lipids [Alabaster, AL] and Sigma), 60 μM malonyl-CoA (Sigma), 6.5 pmol [2-14C]malonyl-CoA (Perkin-Elmer), 1 mM NADPH (Sigma), and 20 μM BSA (fatty acid-free). Reactions (at 37°C) were initiated with the addition of NADPH. When fatty acids were used as substrate, NaOH-neutralized fatty acid (40 μM) replaced fatty acyl-CoA. Coenzyme A (CoASH) (100 μM), MgCl2 (1 mM), and ATP (1 mM) were added to the reaction to generate fatty acyl-CoA. Elongation reactions were terminated after 20 min with the addition of 100 μl of 5 N KOH plus 10% methanol; lipids were saponified for 1 h at 65°C. The saponification reaction was acidified with 100 μl of 5 N HCl; 100 μl of ethanol was added to aid hexane extraction of fatty acids. Elongated fatty acids were collected by two independent extractions with hexane (800 μl). Hexane extracts were pooled, and 14C radioactivity was quantified by β-scintillation counting. Results are expressed as elongase activity units (nmol [14C]malonyl-CoA incorporated/mg protein/20 min). Formation of reaction products was dependent on the presence of NADPH and the fatty acid-CoA. Fatty acid elongation products were verified by reverse-phase HPLC using a flow-through β-scintillation counter (6).

Statistical analysis

Statistical analysis used Student’s t-test and ANOVA plus post hoc Tukey’s honestly significant difference test (http://faculty.vassar.edu/lowry/VassarStats.html).

RESULTS

Elongase and desaturase expression in rat, mouse, and human liver

Our first objective was to compare fatty acid elongase and desaturase expression in rat, mouse, and human liver (Fig. 1A). Of the seven elongases identified in the genomes of these species, qRT-PCR analysis indicated that only four elongases are expressed in liver: Elovl-1, Elovl-2, Elovl-5, and Elovl-6. Based on relative mRNA abundance, the hierarchy of elongase expression in rat, mouse, and human liver is Elovl-5 > Elovl-1 = Elovl-2 = Elovl-6. All elongases are expressed at higher levels in mouse liver than in human liver. Elovl-2 and Elovl-6 are expressed at higher levels in mouse liver than in rat liver.

Fatty acid elongase activity was assessed using three substrates. 16:0-CoA is a substrate for Elovl-1 and Elovl-6; 20:4-CoA is a substrate for Elovl-2 and Elovl-5; and 24:0-CoA is a substrate for Elovl-1 (7). Elongation of 16:0-CoA to 18:0-CoA was highest in mouse liver, whereas elongation of 24:0-CoA to 26:0-CoA was comparable among species. Elongation of 20:4-CoA to 22:4-CoA was lowest in human liver. Differences in elongation activity can be attributed to elongase subtype expression among species. Mouse and rat liver appear to have higher elongation capacity than human liver.

Δ5 desaturase (Δ5D) and Δ6 desaturase (Δ6D) are expressed at comparable levels in livers of all three species. Δ5D is highly expressed in mouse liver compared with rat or human livers. These results reveal important species differences in both elongase and desaturase expression in rat, mouse, and human liver.

Role of PPARα in the control of hepatic elongase and desaturase expression

Feeding rats the PPARα agonist, WY14643, induces certain hepatic fatty acid elongases and desaturases and promotes changes in hepatic and plasma lipid composition (17). Here, we further evaluated the role that PPARα plays in the control of hepatic elongase and desaturase expression. The effect of WY14643 on elongase and desaturase expression in wild-type and PPARα−/− mice was examined. Mice were fed a control diet or one contain-
ing WY14643 (at 50 or 500 mg WY14643/kg diet) for 1 week (Fig. 2). Of the four elongases expressed in mouse liver, WY14643 (500 mg/kg) induced only Elovl-5 and Elovl-6 (14- and 3.6-fold, respectively). Previous studies established that the PPARα agonist increased desaturase expression (26). Our results indicate that Δ5D and Δ5D transcript levels were induced ~6-fold by WY14643 (500 mg/kg), whereas Δ5D was weakly induced. Elovl-1 and Elovl-2 mRNA abundance was unresponsive to WY14643 treatment. The absence of a WY14643 effect on elongase and desaturase expression in PPARα−/− mice indicates that PPARα plays a role in controlling both elongase (Elovl-5 and Elovl-6) and desaturase (Δ5D and Δ3D) expression.

Regulation of elongase and desaturase expression in primary rat hepatocytes

Insulin, SREBP-1c (26, 27), the LXR agonist T0901317 (T1317), glucose, ChREBP, and MLX (24) control desaturase expression (28). The studies described below determined whether these same transcriptional regulatory systems control elongase expression in rat primary hepatocytes.

Regulation of elongases and desaturases by insulin and LXR agonist. Insulin regulates hepatic lipid synthesis, at least in part, by controlling SREBP-1 nuclear abundance (21, 29). LXR agonist stimulates lipogenesis through direct and indirect mechanisms (30). LXR/retnoid X receptor heterodimers bind LXR regulatory element in promoters of responsive lipogenic genes. LXR agonist also induces lipogenic gene expression through the induction of SREBP-1c gene transcription (29, 30). The effect of insulin and T1317 on hepatocyte elongase and desaturase expression was examined.

In the absence of insulin or T1317, SREBP-1 nuclear abundance in hepatocytes was low (Fig. 3, inset). Treatment of rat primary hepatocytes with insulin or T1317 induced nuclear SREBP-1 (~4-fold) but had no effect on SREBP-2 nuclear abundance. T1317 (1 μM) had no significant effect on Elovl-1, Elovl-2, or Elovl-5 expression in rat primary hepatocytes and only modestly induced Elovl-6 ~1.5-fold (Fig. 3). In contrast, all three desaturases were induced between 2- and 15-fold; Δ5D was most responsive. Insulin induced Elovl-6 and Δ5D ≤1.5-fold, whereas Δ5D and Δ3D were induced >3-fold. Cotreatment with insulin and T1317 had no additive effect on SREBP-1 nuclear abundance or the expression of any elongase or desaturase.

These studies suggest that the induction of Elovl-6, Δ5D, Δ3D, and Δ3D by insulin and T1317 likely involves the control of SREBP-1 nuclear abundance. Although others have reported that insulin induces LXRα in primary hepatocytes (31), we found no evidence for an insulin effect on either LXRα or LXRβ mRNA abundance (data not shown). Glucocorticoids, T3, and leptin had no effect on elongase expression in primary rat hepatocytes. None of the hormones tested induced hepatic Elovl-3, Elovl-4, or Elovl-7 (data not shown).

Effect of overexpressed nuclear SREBP-1c on elongase and desaturase expression. To further evaluate the SREBP-1c control of elongase and desaturase expression, primary hepatocytes were infected with a recombinant adenovirus containing a doxycycline-inducible nuclear form of SREBP-1c (Ad-nSREBP-1c) (25). These cells received no insulin or LXR agonist. Treatment of primary hepatocytes with doxycycline significantly induced the nuclear form of SREBP-1c (data not shown) as well as the endogenous SREBP-1 transcript (Fig. 4). The endogenous SREBP-1c promoter contains an SRE and is activated by increased levels of nuclear SREBP (29). Overexpressed nSREBP-1c induced transcripts encoding Elovl-2, Elovl-6, Δ5D, Δ3D, and Δ3D ~3-fold at a doxycycline dose of 250 ng/ml. Modest induction (>1.5-fold) was detected with doxycycline at 25 ng/ml.

We next determined whether insulin or T1317 had any effects on elongase or desaturase expression independent of SREBP-1c. Ad-nSREBP-1c-infected cells were treated with insulin or T1317. Overexpressed SREBP-1c (Ad-SREBP-1c) induced Elovl-2 (2.6-fold) and Elovl-6 (6-fold), whereas Δ5D, Δ3D, and Δ3D transcripts were induced 3.6-, 4.8-, and 3.1-fold, respectively. Addition of insulin had no other effect on the expression of any elongase or desaturase. Addition of T1317 induced only Δ3D (~4-fold) (data not shown). The expression of no other elongase or desaturase was affected by T1317. Based on these results, the induction of Elovl-6, Δ5D, and Δ3D by insulin and T1317 (Fig. 4) is attributable to increased SREBP-1 nuclear abundance. Only

**Fig. 2.** Role of peroxisome proliferator-activated receptor α (PPARα) in the control of hepatic elongase and desaturase expression. Homozygous wild-type (+/+) and PPARα-null (−/−) mice on a Sv/129 genetic background (19, 20) were fed either a control diet or one containing WY14643 (50 or 500 mg/kg diet; BioServ, Piscataway, NJ) for 1 week. Liver RNA was extracted and used as a template for qRT-PCR. Results are reported as fold change in mRNA abundance (transcript/cyclophilin) for each enzyme (means ± SD; n = 4). * P ≤ 0.05 by Student’s t-test versus the wild type (+/+) on a control diet.
Δ^3D expression was induced by increased SREBP-1 nuclear abundance and independently by LXR agonist.

Glucose, ChREBP, and MLX regulation of elongase and desaturase expression. Insulin and glucose are potent inducers of glycolysis and lipogenesis (32, 33). Insulin-stimulated glucose metabolism induces the translocation of ChREBP to the nucleus, where the ChREBP/MLX heterodimer binds carbohydrate-regulatory elements (ChoREs) in promoters of glucose-responsive genes involved in glycolysis and lipogenesis (32, 34). The effect of glucose on elongase and desaturase expression in primary hepatocytes was examined.

Primary hepatocytes were maintained in medium containing lactate (20 mM) and insulin (1 μM) or switched to medium containing 25 mM glucose plus insulin. This approach is consistent with the one used in our previous studies and by other investigators to examine glucose-regulated gene expression in primary hepatocytes (22, 24, 35–43). Glucose and insulin induced the accumulation of ChREBP in hepatocyte nuclei with no effect on MLX nuclear abundance (Fig. 5A). t-type pyruvate kinase (L-PK), a glucose-responsive transcript, is controlled at the transcriptional level by binding the ChREBP/MLX heterodimer to its promoter (24). Switching hepatocytes from lactate to glucose induced mRNA_{L-PK} ~30-fold (Fig. 5). Elovl-6 and Δ^3D mRNAs were induced 7.6- and 10-fold, respectively. No other elongase or desaturase was affected by glucose.

To verify the role that ChREBP/MLX heterodimers play in this regulatory process, primary hepatocytes in lactate-containing medium were infected with recombinant adenovirus expressing luciferase (Ad-Luc) or a dominant negative version of MLX (Ad-dnMLX). MLX is required for ChREBP to bind ChoREs in glucose-responsive promoters. Overexpressed dnMLX attenuates the glucose induction of L-PK (39).

Infected cells with Ad-Luc had no effect on the glucose induction of L-PK, Elovl-6, or Δ^3D (Fig. 5). Infection of cells with Ad-dnMLX completely attenuated the glucose induction of L-PK, Elovl-6, and Δ^3D. Ad-Luc or Ad-dnMLX expression in primary hepatocytes had no effect on Elovl-1, Elovl-2, Elovl-5, Δ^3D, or Δ^5D (data not shown). These studies indicate that glucose regulates both Elovl-6 and Δ^3D expression by mechanisms that control the nuclear abundance of ChREBP and MLX. ChREBP and MLX play no role in the control of Elovl-1, Elovl-2, Elovl-5, Δ^3D, or Δ^5D expression.

Metabolism of fatty acids by fatty acid elongases

Fatty acid elongases have overlapping substrate specificities (7, 44). Here, the substrate specificity of three fatty acid elongases was examined. Ad-Luc, Ad-Elovl-2, Ad-Elovl-5, and Ad-Elovl-6 were used to overexpress these enzymes in rat primary hepatocytes. Substrate specificity was exam-
ined using saturated (16:0), monounsaturated (16:1, n-7), and polyunsaturated (18:3, n-6, 20:5, n-3, and 22:5, n-3) fatty acids. Ad-Luc-infected cells served as a control for basal elongase activity using the various substrates. Ad-Elovl-2-infected hepatocytes elongated only 20:5, n-3 and 22:5, n-3 (Fig. 6). Ad-Elovl-5-infected cells elongated 16:1, n-7, 18:3, n-6, and 20:5, n-3. Ad-Elovl-6-infected cells elongated only 16:0 and 16:1, n-7 (Fig. 6).

Expression of hepatic elongases and desaturases is controlled by PPARα, SREBP-1, and ChREBP/MLX (Figs. 2–5). To determine whether changes in elongase and desaturase activity affect hepatocyte fatty acid composition, primary hepatocytes incubated with insulin (induces SREBP-1), PPARα agonists, and glucose (induces ChREBP) were examined for the capacity to elongate and desaturate [14C]16:0. Primary hepatocytes were maintained in Williams E medium with lactate and no insulin overnight. This treatment effectively decreases SREBP-1 and ChREBP nuclear abundance (21, 22). The next day, cells were treated with lactate- or glucose-containing medium in the absence or presence of insulin and WY14643. All cells received 100 μM [14C]16:0. After 24 h of treatment, cells were harvested for lipid extraction and analysis of elongation and desaturation products by reverse-phase HPLC.

**Fig. 5.** Effect of glucose on elongase and desaturase expression. A: Primary rat hepatocytes in Williams E medium + 10 mM lactate + dexamethasone + insulin were switched to Williams E medium + 25 mM glucose + dexamethasone + insulin. After 24 h of treatment, cells were harvested for extraction of nuclear proteins and RNA. The nuclear abundance of carbohydrate-regulatory element binding protein (ChREBP) and MAX-like factor X (MLX) was measured by immunoblotting at the times indicated (22). B: l-type pyruvate kinase (L-PK), Elovl-6, and Δ9D mRNA abundance was quantified by qRT-PCR (transcript/cyclophilin). Results are expressed as fold induction by glucose (means ± SD; n = 4). C: In a second experiment, primary hepatocytes in Williams E medium + 10 mM lactate + dexamethasone + insulin remained uninfected (white bars) or were infected with recombinant adenovirus expressing luciferase (Ad-Luc; black bars) or dominant negative MLX (Ad-dnMLX; gray bars). After 24 h, cells were switched to Williams E medium + 25 mM glucose + dexamethasone + insulin. Twenty-four hours later, cells were harvested for RNA extraction and measurement of L-PK, Elovl-6, and Δ9D mRNA by qRT-PCR (transcript/cyclophilin). Results are represented as relative mRNA abundance relative to glucose-treated cells (means ± SD; n = 4). Results are representative of two separate studies. * P < 0.001 versus glucose-treated cells by ANOVA.

**Fig. 6.** Substrate specificity of hepatic fatty acid elongases. Ad-Luc, Elovl-2, Elovl-5, and Elovl-6 were used to infect primary hepatocytes (5 plaque-forming units/cell). After 24 h, cells were harvested for elongase activity using various fatty acid substrates (see Materials and Methods). Results are expressed as elongase activity (nmol [14C]malonyl-CoA assimilated into fatty acid/mg protein) (means ± SD; n = 3). Results are representative of two separate studies.
Cells maintained in lactate medium with no insulin or WY14643 did not desaturate 16:0 (Fig. 7), but these cells had the capacity to elongate 16:0 to 18:0. Addition of insulin or WY14643 to lactate-treated cells induced the formation of 16:1,n-7, whereas only WY14643 induced the formation of 18:1 (n-7 and n-9). The combination of these treatments had no additive effect.

Switching cells to glucose-containing medium promoted 16:0 desaturation to 16:1,n-7 as well as elongation and desaturation of 16:0 to 18:1 (n-7 and n-9). The combination of glucose plus insulin or glucose plus WY14643 induced the formation of both 16:1,n-7 and 18:1 (n-7 and n-9) synergistically. Glucose, insulin, and WY14643 had no apparent effect on the elongation of 16:0 to 18:0. Because 18:0 is a substrate for Δ⁹D, measuring changes in 18:0 may not accurately reflect changes in elongation activity. In an effort to reveal an effect on elongation, we examined the effect of glucose, insulin, and WY14643 on the 18:1-to-16:1 ratio (Fig. 7D). This ratio (elongation index) would remain constant if these treatments did not regulate elongation. The most impressive effect on the 18:1-to-16:1 ratio was seen in cells maintained in lactate-containing medium supplemented with WY14643. Such studies indicate that hepatocyte levels of 18:1 (n-7 and n-9) are controlled by both elongation and desaturation pathways. The elongation pathway is not a constitutive pathway. Cellular levels of 18:1 are not determined solely by changes in Δ⁹D expression.

**Regulation of elongase and desaturase expression in animal models of metabolic disease**

PPARα (45), SREBP-1 (46) and glucose metabolism, ChREBP and MLX (32), and LXR (47) play important roles in metabolic diseases such as diabetes and obesity. Here, we sought to determine whether changes in hepatic lipid metabolism and composition induced by diabetes and obesity can be attributed to changes in elongase and desaturase expression. Three metabolic disorders were

![Fig. 7. Effects of insulin and WY14643 on monounsaturated fatty acid synthesis.](image-url)
examined: streptozotocin-induced diabetes, glucose intolerance induced by high-fat diets, and obesity induced by leptin deficiency. Nuclear levels of SREBP-1, ChREBP, MLX, and HNF-4α were monitored. We wanted to determine whether changes in the nuclear content of these transcription factors correlated with changes in elongase or desaturase expression.

**Streptozotocin-induced diabetes.** Rats made diabetic using streptozotocin had high blood glucose (378 ± 21 mg/dl) compared with control animals (77.9 ± 5.2 mg/dl). Liver nuclei from diabetic rats contained little detectable nuclear SREBP-1 and suppressed levels of MLX, but there was no significant change in ChREBP or HNF-4α (Fig. 8A). Diabetes suppressed the expression of lipogenic and glycolytic genes (e.g., fatty acid synthase and L-PK) by ≥70% (18), whereas expression of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase was induced 3-fold (18). The decline in the nuclear abundance of SREBP-1 and MLX correlated with an ≥45% decline in Elovl-6 and a ≥95% decline in Δ^9D mRNA abundance. Other elongases and desaturases remained unaffected. Examination of hepatic lipid composition revealed a significant 30% decline in 16:0 in diabetic animals but no change in other saturated, monounsaturated, or polyunsaturated fatty acids (data not shown). The decline in 16:0 is consistent with the decline in de novo lipogenesis in livers of diabetic rats (18).

**Glucose intolerance induced by high-fat diets.** High-fat diets induce glucose intolerance, insulin resistance, fatty liver, and altered hepatic metabolism (48, 49). To examine the effects of diet-induced diabetes on elongase and desaturation expression, male C57BL/6J mice were fed a diet with 10% of the calories as fat (low-fat-lard diet) or 60% of the calories as fat (high-fat-lard diet). Animals fed the low-fat diet were ~29 g and had blood glucose and insulin levels within the normal range, 121 mg/dl and 0.5 ng/ml (Table 2). Animals fed the high-fat-lard diet were ~44 g with increased blood glucose (152 mg/dl) and insulin (3.9 ng/ml). Compared with the low-fat-group, high-fat-fed animals were glucose intolerant (Fig. 9A) and had fatty livers (48). Nuclear levels of SREBP-1 and MLX were suppressed 60% and 50% (Fig. 9B), whereas ChREBP and HNF-4α nuclear levels remained unchanged.

Expression levels of Elovl-1 and Elovl-2 were not significantly affected by high dietary fat (Fig. 9C). Elovl-5 and Elovl-6 mRNA abundance, however, was suppressed by 50% and 75% with the high fat intake. The high-fat diet had no effect on Δ^9D or Δ^4D but significantly suppressed Δ^9D fatty acid elongation (≥80%). High-fat diets significantly suppressed fatty acid elongation of 16:0-CoA and 20:4-CoA but not 24:0-CoA (Fig. 9D).

Palmitic (16:0), stearic (18:0), oleic (18:1,n-9), and linoleic (18:2,n-6) acids represent the major fatty acids in both diets. Analysis of hepatic lipid composition indicated that 18:2,n-6 accumulated relative to 20:4,n-6 in livers of high-fat-fed animals (data not shown). 18:2,n-6, an essential fatty acid, is converted to 20:4,n-6. Because neither diet contained 20:4,n-6, the appearance of 20:4,n-6 in the livers required conversion from 18:2,n-6 to 20:4,n-6 by elongation (Elovl-2 and Elovl-5) and desaturation (Δ^5D and Δ^4D). In the low-fat diet, the ratio of 20:4,n-6 to 18:2,n-6 was 0.75. In the high-fat diet, the ratio was 0.3. Failure to convert 18:2,n-6 to 20:4,n-6 is consistent with a decline in Elovl-5 expression, a key enzyme involved in PUFA synthesis.

**Elongase and desaturase expression in livers of lean (Lep^ob/+^) and obese (Lep^ob/ob^) mice.** Defective leptin expression in C57BL/6J-Lep^ob/ob^ mice leads to hyperphagia, hyperinsulinemia, insulin resistance, and obesity (50). Compared with their lean (Lep^ob/+^) littermates, obese animals were heavier and had increased blood levels of glucose and insulin (Table 2). The livers of obese mice were massively engorged with lipid, predominantly as neutral lipid. Hepatic nuclei derived from obese mice had a 2.6- and 2-fold...
increase in SREBP-1 and MLX nuclear abundance but no change in ChREBP or HNF-4α compared with those of lean littermates. Expression levels of Elovl-5, Elovl-6, Δ5D, Δ6D, and Δ9D were increased in livers of obese mice compared with their lean littermates. Obesity also resulted in the induction of lipogenic gene expression (ACC, FAS) and PPARα target genes, such as cytochrome P450 4A (Cyp4A) and acyl CoA oxidase (data not shown). Fatty acid elongation of 16:0-CoA was increased 2-fold, whereas elongation of 20:4-CoA and 24:0-CoA was not affected (Fig. 10C).

Fatty acid analysis of livers from lean and obese mice revealed an ~9-fold increase in total esterified fatty acid. Much of this increase is in the form of neutral lipid esterified with 18:1 (n-7 and n-9) (Fig. 10D). Although mono-unsaturated fatty acid abundance increased, hepatic PUFA content (i.e., 18:2, n-6, 20:4, n-6, and 22:6, n-3) declined. This might appear inconsistent with the observed increase in fatty acid elongase activity and elongase and desaturase expression. Lepob/ob mice, however, are hyperphagic; ingestion of excessive calories as carbohydrate increased plasma insulin (Table 2) and enhanced de novo lipogen-
esis and monounsaturated fatty acid synthesis. Induction of Elovl-5, Elovl-6, and Δ⁹D expression by activated PPARα and increased SREBP-1 and MLX nuclear content facilitated monounsaturated fatty acid (18:1, n-7 and 18:1, n-9) synthesis, which was assimilated into neutral lipid. Protein levels were measured by immunoblot analysis (see Materials and Methods). Triplicate samples for each phenotype are shown. The effect of leptin deficiency on the abundance of these proteins was quantified and expressed as fold change (means; n = 4) induced by leptin deficiency. Statistical significance (P) was assessed by Student’s t-test. B: Effect of leptin deficiency on elongase and desaturase expression. RNA was extracted and used for qRT-PCR analysis of elongase and desaturase expression. Results are expressed as fold change (transcript/cyclophilin) (means ± SD; n = 4). * P < 0.01 versus lean by Student’s t-test. C: Effect of leptin deficiency on elongase activity. Hepatic microsomal preparations were used for fatty acid elongase assays (see Materials and Methods). Results are expressed as elongase activity (nmol [14C]malonyl-CoA assimilated into fatty acids/mg protein) (means ± SD; n = 4). * P < 0.01 versus lean by Student’s t-test. D: Effect of leptin deficiency on hepatic lipid composition. Total lipids were extracted and saponified; fatty acid levels were quantified by reverse-phase HPLC (see Materials and Methods). Results are expressed as fatty acid mol% (means ± SD; n = 4/group). * P < 0.01 versus lean animals by Student’s t-test.

DISCUSSION

Fatty acid elongation and desaturation are two key metabolic routes for the synthesis of saturated, monounsaturated, and polyunsaturated fatty acids. Of these, fatty acid desaturases have received considerable attention for their regulation by hormones and nutrients and their capacity to generate specific unsaturated fatty acids. The outcome of these studies indicates that desaturases are well-regulated enzymes that play an important role in cellular and whole body lipid composition (28, 51). One of these enzymes, Δ⁹D (stearoyl-CoA desaturase-1), has emerged as a key enzyme in the control of whole body lipid composition (52).

In contrast to the desaturases, fatty acid elongases have only recently been recognized as proteins regulated at the pretranslational level (11, 44, 53). Fatty acid elongases are regulated by tissue-specific and nutritional factors and during postnatal development (17). Such studies implicated certain transcription factors, such as SREBP-1 and PPARα, as regulators of both elongase and desaturase expression. This report extends those previous observations by evaluating the role of several hormones (insulin, T₃, glucocorticoids, and leptin), transcription factors (SREBP-1c, PPARα, LXR, ChREBP, and MLX), and nutrients (glucose and fat) in the control of hepatic elongase and desaturase gene expression, fatty acid elongase activity, and lipid composition. Finding the involvement of these transcription factors in the control of elongase expression prompted studies to evaluate how these enzymes were regulated in metabolic disease. The outcome of these studies has provided new information on how changes in both elongase and desaturase expression in metabolic disease contribute to hepatic lipid composition.
Seven fatty acid elongase subtypes (Elovl-1 to Elovl-7) have been identified in the genomes of the rat, mouse, and human (www.ensembl.org). Of these, four elongase subtypes are expressed in rat, mouse, and human liver (Fig. 1). The hierarchy for hepatic expression of these enzymes is similar in all three species: Elovl-5 > Elovl-1 = Elovl-2 = Elovl-6. Analysis of elongase activity indicates that mouse liver has the highest elongase activity.

**Elovl-1**

Elovl-1 is a low-abundance elongase in liver of all three species. Based on studies in yeast, Elovl-1 elongates a broad array of saturated and monounsaturated fatty acids. Elovl-1 expression, however, is not regulated by any physiological manipulation used to date in this or our previous study (17). Thus, changes in hepatic lipid composition induced during postnatal development or in association with fasting and refeeding, diabetes, obesity, dietary fat, LXR, or PPARα agonist cannot be attributed to changes in Elovl-1 activity. Hepatic Elovl-1 appears to be expressed constitutively.

**Elovl-2**

Elovl-2 is also a low-abundance elongase in liver of all three species. In contrast to other elongases, Elovl-2 has a very narrow substrate preference: it elongates C20 and C22 PUFAs (Fig. 6). As such, Elovl-2 participates in the conversion of essential fatty acid precursors to end products of PUFAs (i.e., 20:4, n-6 and 22:6, n-3). Like Elovl-1, Elovl-2 is not regulated by any factors examined in this or our previous report (17). The exception to this is the induction of Elovl-2 mRNA after overexpression of SREBP-1c (Fig. 3). Because insulin, LXR agonist, and glucose fail to induce this transcript, we feel that the induction of Elovl-2 by overexpressed SREBP-1c may have limited physiological significance in vivo.

**Elovl-5**

Elovl-5 is the most abundant elongase transcript in all three species. It also is expressed in many tissues, induced during postnatal development, and suppressed by feeding rats n-3 PUFA-enriched diets (17). Several hormones (insulin, T₃, glucocorticoids, and leptin) and transcription factors (SREBP-1c, LXR, ChREBP, and MLX) have no impact on hepatic Elovl-5 expression. Only PPARα, n-3 PUFA-enriched diets (17), high-fat diets (Fig. 9), and obesity (Fig. 10) affect Elovl-5 expression. The regulation of Elovl-5 is physiologically significant. Feeding rats a high-carbohydrate diet supplemented with olive oil plus WY14643 significantly increased mead acid (20:3, n-9) production (17). Mead acid is an elongation and desaturation product of 18:1, n-9, the predominant fatty acid in olive oil. WY14643 induction of Elovl-5 likely contributes to the formation of 20:3, n-9. Elovl-5 also converts 16:1, n-7, but not 16:0, to an 18 carbon mono-unsaturated fatty acid (18:1, n-7) (Fig. 6) as well as the elongation of an intermediate (18:3, n-6) in the pathway for n-6 PUFA synthesis (20:4, n-6) (Fig. 6). Suppression of Elovl-5 in high-fat-fed mice correlates with a decreased hepatic 20:4, n-6-to-18:2, n-6 ratio (Fig. 9). Enhanced Elovl-5 expression correlates with the increased content of 18 carbon monounsaturated fatty acids in livers of obese mice (Lep½/ob) (Fig. 10). Many PPARα-regulated transcripts, such as acyl-CoA oxidase and Cyp4A, are induced in livers of Lep½/ob mice (data not shown). Induction of Elovl-5 in livers of obese mice is likely attributable to PPARα activation.

Despite the role that Elovl-5 plays in PUFAs and its increase in livers of obese mice, hepatic lipids in obese animals are not enriched in PUFAs. In fact, obese livers are depleted of PUFA relative to other fatty acids, such as 18:1 (Fig. 10D). Δ⁵D, Δ⁷D, and Δ⁹D are induced in livers of obese mice, but to differing extents (Fig. 10D). Δ⁵D and Δ⁷D are induced in obese liver as a result of the increased nuclear abundance of SREBP-1 and activation of PPARα. Δ⁹D is induced by these same transcription factors, plus increased nuclear ChREBP/MLX (Fig. 10D). Thus, hyperphagia resulting from defective leptin production, coupled with the ingestion of the high-carbohydrate diet, stimulates de novo lipogenesis and monounsaturated fatty acid synthesis. In this instance, Elovl-5 substrates, in particular 16:1, n-7 (Fig. 6), are end products of de novo lipogenesis, and Δ⁹D. Increased expression of Elovl-5, Elovl-6, and Δ⁹D, coupled with enhanced production of end products of de novo lipogenesis, increases 18:1, n-7 and 18:1, n-9 production.

**Elovl-6**

Elovl-6 is expressed at low levels in livers of all three species. Like Elovl-2, Elovl-6 has a narrow substrate preference (i.e., C₁₂-16 saturated and unsaturated fatty acids) (17) (Fig. 6) (10). In contrast to other elongases, Elovl-6 is regulated by multiple factors. Insulin and LXR agonist increase SREBP-1 nuclear abundance, which leads to induced Elovl-6 expression (Figs. 3, 4). Insulin-induced glucose metabolism increases ChREBP nuclear content, and the ChREBP/MLX heterodimer regulates glucose-regulated genes, including L-PK, ACC, FAS, and Δ⁹D. Elovl-6 is among these glucose-regulated genes (Fig. 5). PPARα activation also induces Elovl-6 (Fig. 2). Elovl-6 is regulated during postnatal development, but unlike Elovl-5, Elovl-6 expression declines at birth and is induced at weaning. Elovl-6 expression during early postnatal development parallels SREBP-1 nuclear abundance (17). The finding that both Elovl-6 and Δ⁹D are induced along with L-PK and FAS (Fig. 10) indicates that these enzymes play a role in the hepatic response to excess carbohydrate consumption.

Excess carbohydrate is channeled to de novo lipogenesis via enhanced L-PK activity. Insulin-stimulated glucose metabolism induces ChREBP translocation into hepatic nuclei (32, 54, 55). ChREBP and MLX heterodimers bind ChREBs in promoters of responsive genes, such as L-PK, ACC, and FAS. Insulin also increases SREBP-1 nuclear abundance, leading to increased promoter occupancy of SREBP-1 on SRE in target genes (e.g., ACC, FAS, and Δ⁹D). Consistent with this scenario is the increased nuclear abundance of SREBP-1 and MLX in livers derived from obese animals (Fig. 10). The end product of de novo lipogenesis, 16:0, is elongated (Elovl-6) and desaturated...
(Δ⁹D) to yield 18:1, the fatty acid that accumulates in livers of obese mice. In this metabolic scheme, there appears to be a tight coordination between glycolysis, de novo lipogenesis, fatty acid elongation (Elovl-6), and desaturation (Δ⁶D) that involves three transcription factors: ChREBP, MLX, and SREBP-1c.

Although these studies provide a link between ChREBP, MLX, SREBP-1, and PPARα in the control of elongase expression, the mechanism(s) for this control remains undefined. Whether this control involves direct interaction of these transcription factors with regulatory elements in the promoters of the elongases or indirect control through other mechanisms will require detailed analysis of the promoters for Elovl-5 and Elovl-6. Such studies are beyond the scope of this report.

In conclusion, we have established that specific hepatic fatty acid elongases, Elovl-5 and Elovl-6, are regulated in liver by nutrients (glucose and fat), hormones (insulin), and nuclear receptor agonists (i.e., LXR and PPARα agonist). ChREBP, MLX, SREBP-1, and PPARα control both elongase and desaturase expression. Only Δ⁶D is independently regulated by LXR. Metabolic diseases, such as diabetes and obesity, induce changes in hepatic lipid composition by controlling the function of key transcription factors that affect elongase and desaturase expression. These studies support the notion that the regulation of both fatty acid elongase and desaturase expression may play an important role in managing hepatic lipid composition in response to changes in dietary and hormonal status.

The authors thank Howard C. Towle (University of Minnesota) for generously providing the recombinant adenovirus expressing SREBP-1c nuclear form and the dominant negative MLX. The authors also thank Kate Claycomb and Dale Romsos (Michigan State University) for the generous supply of livers from lean and obese mice. This project was supported by the National Institutes of Health (Grant DK-13220), the National Research Initiative of the U.S. Department of Agriculture Cooperative State Research, Education, and Extension Service (2003-35200-13400), and the Michigan Agriculture Experiment Station.

REFERENCES


ERRATA

In the article “Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity,” published in the September 2006 issue of the Journal of Lipid Research (Volume 47, pages 2028-2041), the author and affiliation lines contained errors. The correct author names and affiliations for this article should read:

Yun Wang,*,1 Daniela Botolin,*,1 Jinghua Xu,†,1 Barbara Christian,* Ernestine Mitchell,* Bolleddula Jayaprakasam,§ Muraleedharan G. Nair,§ Jeffrey M. Peters,** Julia V. Busik,* L. Karl Olson,* and Donald B. Jump2,*,†

Department of Physiology,* Biochemistry and Molecular Biology,† and Horticulture and National Food Safety and Toxicology Center,** Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802

AUTHOR INDEX Volume 47, Number 10